-+ 0.00%
-+ 0.00%
-+ 0.00%

Biodexa Pharma Partners With Syngene International To Manufacture Both MTX240 Active Pharmaceutical Ingredient And Dosage Form

Benzinga·04/02/2026 12:37:47
Listen to the news

Biodexa Announces Partnership with Syngene

To Manufacture MTX240 GMP Clinical Trial Supplies

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) ("Syngene") for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form.